Identifying novel pathways at the interface of immunity and metabolism

About Us

Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class therapeutics for patients with autoimmune disease. The Company’s mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm. We are working hard to become the next Immunology Development Powerhouse.

Landos was established as an incredibly productive research engine, with a portfolio of three novel targets anchoring libraries of immunometabolic modulation pathways, including seven first-in-class, once-daily therapies targeting 14 indications in the immunology space. This includes our three clinical stage programs: NX-13 for Ulcerative Colitis and Crohn’s Disease; Omilancor for Ulcerative Colitis, Crohn’s Disease and Eosinophilic Esophagitis; and LABP-104 for Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA).

Our lead product candidate, NX-13, targets the NLRX1 pathway, a mitochondrial-associated regulatory NOD-like receptor. NX-13 is orally-active and gut-selective, allowing target engagement within the GI tract.

In August 2022, the Company reported positive top-line results from a NX-13 Phase 1b trial, demonstrating a favorable safety and tolerability profile in Ulcerative Colitis patients across a range of once-daily doses. Results also indicate promising early signals of clinical improvement as soon as two weeks in patients’ symptoms and four weeks by endoscopy in exploratory endpoints.

The Company is planning to initiate a Phase 2 proof of concept trial to evaluate the safety, efficacy and optimal dosing of NX-13 in UC patients in the second quarter of 2023.

Management Team

Gregory Oakes

President & CEO

Read More about Gregory Oakes

Fabio Cataldi, M.D.

Chief Medical Officer

Read More about Fabio Cataldi, M.D.

Board of Directors

Gregory Oakes

President & CEO

Read More about Gregory Oakes

Chris Garabedian


Read More about Chris Garabedian

Roger Adsett

Chief Operating Office of Insmed, Inc.

Read More about Roger Adsett

Fred Callori

Xontogeny, Perceptive Advisors

Read More about Fred Callori

Tiago Girão

CFO of Proteovant Therapeutics

Read More about Tiago Girão

Tim M. Mayleben


Read More about Tim M. Mayleben